Electronic Design Automation (EDA) Software
Electronic Design Automation (EDA) Software market is segmented by region (country), players, by ... Read More
Global and United States Metabolic Disorder Therapeutics Market Report & Forecast 2024-2031
1 Study Coverage
1.1 Metabolic Disorder Therapeutics Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Metabolic Disorder Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Metabolic Disorder Therapeutics Market Size for the Year 2017-2028
1.2.2 Global Metabolic Disorder Therapeutics Market Size for the Year 2017-2028
1.3 Metabolic Disorder Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Metabolic Disorder Therapeutics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Metabolic Disorder Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Metabolic Disorder Therapeutics Market Dynamics
1.4.1 Metabolic Disorder Therapeutics Industry Trends
1.4.2 Metabolic Disorder Therapeutics Market Drivers
1.4.3 Metabolic Disorder Therapeutics Market Challenges
1.4.4 Metabolic Disorder Therapeutics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Metabolic Disorder Therapeutics by Type
2.1 Metabolic Disorder Therapeutics Market Segment by Type
2.1.1 Lysosomal Storage Diseases
2.1.2 Diabetes
2.1.3 Obesity
2.1.4 Inherited Metabolic Disorders
2.1.5 Hypercholesterolemia
2.2 Global Metabolic Disorder Therapeutics Market Size by Type (2017, 2022 & 2028)
2.3 Global Metabolic Disorder Therapeutics Market Size by Type (2017-2028)
2.4 United States Metabolic Disorder Therapeutics Market Size by Type (2017, 2022 & 2028)
2.5 United States Metabolic Disorder Therapeutics Market Size by Type (2017-2028)
3 Metabolic Disorder Therapeutics by Application
3.1 Metabolic Disorder Therapeutics Market Segment by Application
3.1.1 Oral
3.1.2 Parenteral
3.1.3 Others
3.2 Global Metabolic Disorder Therapeutics Market Size by Application (2017, 2022 & 2028)
3.3 Global Metabolic Disorder Therapeutics Market Size by Application (2017-2028)
3.4 United States Metabolic Disorder Therapeutics Market Size by Application (2017, 2022 & 2028)
3.5 United States Metabolic Disorder Therapeutics Market Size by Application (2017-2028)
4 Global Metabolic Disorder Therapeutics Competitor Landscape by Company
4.1 Global Metabolic Disorder Therapeutics Market Size by Company
4.1.1 Top Global Metabolic Disorder Therapeutics Companies Ranked by Revenue (2021)
4.1.2 Global Metabolic Disorder Therapeutics Revenue by Player (2017-2022)
4.2 Global Metabolic Disorder Therapeutics Concentration Ratio (CR)
4.2.1 Metabolic Disorder Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Metabolic Disorder Therapeutics in 2021
4.2.3 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Metabolic Disorder Therapeutics Headquarters, Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Metabolic Disorder Therapeutics Headquarters and Area Served
4.3.2 Global Metabolic Disorder Therapeutics Companies Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Metabolic Disorder Therapeutics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Metabolic Disorder Therapeutics Market Size by Company
4.5.1 Top Metabolic Disorder Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Metabolic Disorder Therapeutics Revenue by Players (2020, 2021 & 2022)
5 Global Metabolic Disorder Therapeutics Market Size by Region
5.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Metabolic Disorder Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Metabolic Disorder Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Metabolic Disorder Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Metabolic Disorder Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novo Nordisk A/S
7.1.1 Novo Nordisk A/S Company Details
7.1.2 Novo Nordisk A/S Business Overview
7.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
7.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.1.5 Novo Nordisk A/S Recent Development
7.2 Sanofi S.A.
7.2.1 Sanofi S.A. Company Details
7.2.2 Sanofi S.A. Business Overview
7.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
7.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.2.5 Sanofi S.A. Recent Development
7.3 Boehringer Ingelheim GmbH
7.3.1 Boehringer Ingelheim GmbH Company Details
7.3.2 Boehringer Ingelheim GmbH Business Overview
7.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
7.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.3.5 Boehringer Ingelheim GmbH Recent Development
7.4 Eli Lilly and Company
7.4.1 Eli Lilly and Company Company Details
7.4.2 Eli Lilly and Company Business Overview
7.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
7.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.4.5 Eli Lilly and Company Recent Development
7.5 Merck KgaA
7.5.1 Merck KgaA Company Details
7.5.2 Merck KgaA Business Overview
7.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
7.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.5.5 Merck KgaA Recent Development
7.6 Amgen, Inc.
7.6.1 Amgen, Inc. Company Details
7.6.2 Amgen, Inc. Business Overview
7.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
7.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.6.5 Amgen, Inc. Recent Development
7.7 AstraZeneca PLC
7.7.1 AstraZeneca PLC Company Details
7.7.2 AstraZeneca PLC Business Overview
7.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
7.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.7.5 AstraZeneca PLC Recent Development
7.8 Actelion Pharmaceuticals Ltd.
7.8.1 Actelion Pharmaceuticals Ltd. Company Details
7.8.2 Actelion Pharmaceuticals Ltd. Business Overview
7.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
7.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.8.5 Actelion Pharmaceuticals Ltd. Recent Development
7.9 Shire PLC
7.9.1 Shire PLC Company Details
7.9.2 Shire PLC Business Overview
7.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
7.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.9.5 Shire PLC Recent Development
7.10 AbbVie, Inc.
7.10.1 AbbVie, Inc. Company Details
7.10.2 AbbVie, Inc. Business Overview
7.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
7.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.10.5 AbbVie, Inc. Recent Development
7.11 Biocon Ltd.
7.11.1 Biocon Ltd. Company Details
7.11.2 Biocon Ltd. Business Overview
7.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
7.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.11.5 Biocon Ltd. Recent Development
7.12 BioMarin Pharmaceutical, Inc.
7.12.1 BioMarin Pharmaceutical, Inc. Company Details
7.12.2 BioMarin Pharmaceutical, Inc. Business Overview
7.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
7.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.12.5 BioMarin Pharmaceutical, Inc. Recent Development
7.13 Bristol-Myers Squibb Company
7.13.1 Bristol-Myers Squibb Company Company Details
7.13.2 Bristol-Myers Squibb Company Business Overview
7.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
7.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.13.5 Bristol-Myers Squibb Company Recent Development
7.14 Cipla, Inc.
7.14.1 Cipla, Inc. Company Details
7.14.2 Cipla, Inc. Business Overview
7.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
7.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.14.5 Cipla, Inc. Recent Development
7.15 CymaBay Therapeutics, Inc.
7.15.1 CymaBay Therapeutics, Inc. Company Details
7.15.2 CymaBay Therapeutics, Inc. Business Overview
7.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
7.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
7.15.5 CymaBay Therapeutics, Inc. Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Metabolic Disorder Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Metabolic Disorder Therapeutics Market Trends
Table 3. Metabolic Disorder Therapeutics Market Drivers
Table 4. Metabolic Disorder Therapeutics Market Challenges
Table 5. Metabolic Disorder Therapeutics Market Restraints
Table 6. Global Metabolic Disorder Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Metabolic Disorder Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Metabolic Disorder Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Metabolic Disorder Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Metabolic Disorder Therapeutics Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Metabolic Disorder Therapeutics Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Metabolic Disorder Therapeutics Revenue Share by Player, 2017-2022
Table 13. Global Metabolic Disorder Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Metabolic Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2021)
Table 15. Top Players of Metabolic Disorder Therapeutics in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Metabolic Disorder Therapeutics Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Metabolic Disorder Therapeutics Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Metabolic Disorder Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Metabolic Disorder Therapeutics Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Metabolic Disorder Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Metabolic Disorder Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Metabolic Disorder Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Metabolic Disorder Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Metabolic Disorder Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Metabolic Disorder Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Metabolic Disorder Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Metabolic Disorder Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Novo Nordisk A/S Company Details
Table 31. Novo Nordisk A/S Business Overview
Table 32. Novo Nordisk A/S Metabolic Disorder Therapeutics Product
Table 33. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 34. Novo Nordisk A/S Recent Development
Table 35. Sanofi S.A. Company Details
Table 36. Sanofi S.A. Business Overview
Table 37. Sanofi S.A. Metabolic Disorder Therapeutics Product
Table 38. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 39. Sanofi S.A. Recent Development
Table 40. Boehringer Ingelheim GmbH Company Details
Table 41. Boehringer Ingelheim GmbH Business Overview
Table 42. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product
Table 43. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 44. Boehringer Ingelheim GmbH Recent Development
Table 45. Eli Lilly and Company Company Details
Table 46. Eli Lilly and Company Business Overview
Table 47. Eli Lilly and Company Metabolic Disorder Therapeutics Product
Table 48. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Eli Lilly and Company Recent Development
Table 50. Merck KgaA Company Details
Table 51. Merck KgaA Business Overview
Table 52. Merck KgaA Metabolic Disorder Therapeutics Product
Table 53. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Merck KgaA Recent Development
Table 55. Amgen, Inc. Company Details
Table 56. Amgen, Inc. Business Overview
Table 57. Amgen, Inc. Metabolic Disorder Therapeutics Product
Table 58. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Amgen, Inc. Recent Development
Table 60. AstraZeneca PLC Company Details
Table 61. AstraZeneca PLC Business Overview
Table 62. AstraZeneca PLC Metabolic Disorder Therapeutics Product
Table 63. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 64. AstraZeneca PLC Recent Development
Table 65. Actelion Pharmaceuticals Ltd. Company Details
Table 66. Actelion Pharmaceuticals Ltd. Business Overview
Table 67. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product
Table 68. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Actelion Pharmaceuticals Ltd. Recent Development
Table 70. Shire PLC Company Details
Table 71. Shire PLC Business Overview
Table 72. Shire PLC Metabolic Disorder Therapeutics Product
Table 73. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Shire PLC Recent Development
Table 75. AbbVie, Inc. Company Details
Table 76. AbbVie, Inc. Business Overview
Table 77. AbbVie, Inc. Metabolic Disorder Therapeutics Product
Table 78. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 79. AbbVie, Inc. Recent Development
Table 80. Biocon Ltd. Company Details
Table 81. Biocon Ltd. Business Overview
Table 82. Biocon Ltd. Metabolic Disorder Therapeutics Product
Table 83. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Biocon Ltd. Recent Development
Table 85. BioMarin Pharmaceutical, Inc. Company Details
Table 86. BioMarin Pharmaceutical, Inc. Business Overview
Table 87. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product
Table 88. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 89. BioMarin Pharmaceutical, Inc. Recent Development
Table 90. Bristol-Myers Squibb Company Company Details
Table 91. Bristol-Myers Squibb Company Business Overview
Table 92. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product
Table 93. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Bristol-Myers Squibb Company Recent Development
Table 95. Cipla, Inc. Company Details
Table 96. Cipla, Inc. Business Overview
Table 97. Cipla, Inc. Metabolic Disorder Therapeutics Product
Table 98. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 99. Cipla, Inc. Recent Development
Table 100. CymaBay Therapeutics, Inc. Company Details
Table 101. CymaBay Therapeutics, Inc. Business Overview
Table 102. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product
Table 103. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
Table 104. CymaBay Therapeutics, Inc. Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Metabolic Disorder Therapeutics Product Picture
Figure 2. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Metabolic Disorder Therapeutics Market Size 2017-2028 (US$ Million)
Figure 4. United States Metabolic Disorder Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Metabolic Disorder Therapeutics Market Size 2017-2028 (US$ Million)
Figure 6. United States Metabolic Disorder Therapeutics Market Share in Global 2017-2028
Figure 7. Metabolic Disorder Therapeutics Report Years Considered
Figure 8. Product Picture of Lysosomal Storage Diseases
Figure 9. Product Picture of Diabetes
Figure 10. Product Picture of Obesity
Figure 11. Product Picture of Inherited Metabolic Disorders
Figure 12. Product Picture of Hypercholesterolemia
Figure 13. Global Metabolic Disorder Therapeutics Market Share by Type in 2022 & 2028
Figure 14. Global Metabolic Disorder Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 15. Global Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
Figure 16. United States Metabolic Disorder Therapeutics Market Share by Type in 2022 & 2028
Figure 17. United States Metabolic Disorder Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 18. United States Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
Figure 19. Product Picture of Oral
Figure 20. Product Picture of Parenteral
Figure 21. Product Picture of Others
Figure 22. Global Metabolic Disorder Therapeutics Market Share by Application in 2022 & 2028
Figure 23. Global Metabolic Disorder Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 24. Global Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
Figure 25. United States Metabolic Disorder Therapeutics Market Share by Application in 2022 & 2028
Figure 26. United States Metabolic Disorder Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 27. United States Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
Figure 28. North America Metabolic Disorder Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 29. U.S. Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 30. Canada Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Europe Metabolic Disorder Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 32. Germany Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. France Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. U.K. Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Italy Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Russia Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Metabolic Disorder Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 38. China Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Japan Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. South Korea Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. India Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Australia Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Taiwan Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Indonesia Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Thailand Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Malaysia Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Philippines Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Latin America Metabolic Disorder Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 49. Mexico Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Brazil Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Argentina Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 53. Turkey Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. U.A.E Metabolic Disorder Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 57. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 58. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 59. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 60. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 61. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 62. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 63. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 64. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 65. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 66. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 67. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 68. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 69. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 70. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novo Nordisk A/S Sanofi S.A. Boehringer Ingelheim GmbH Eli Lilly and Company Merck KgaA Amgen, Inc. AstraZeneca PLC Actelion Pharmaceuticals Ltd. Shire PLC AbbVie, Inc. Biocon Ltd. BioMarin Pharmaceutical, Inc. Bristol-Myers Squibb Company Cipla, Inc. CymaBay Therapeutics, Inc.